Stock Track | Summit Therapeutics Soars 5.14% as Goldman Initiates Coverage with Buy Rating on Promising Drug

Stock Track

02-28

Summit Therapeutics PLC (SMMT) witnessed a surge of 5.14% during the intraday trading session on Friday, reflecting the positive sentiment following Goldman Sachs' initiation of coverage on the stock.

Goldman Sachs analyst Salveen Richter initiated coverage on Summit Therapeutics with a Buy rating and a price target of $42. The analyst is optimistic about the potential of Summit's lead drug candidate, ivonescimab, which is currently undergoing clinical trials for the treatment of Duchenne muscular dystrophy (DMD).

Analysts believe that if the trials for ivonescimab prove successful, it could potentially become a game-changer in the treatment of DMD, a rare genetic disorder characterized by progressive muscle degeneration. The positive coverage from a prominent investment bank like Goldman Sachs has boosted investor confidence in Summit Therapeutics, driving the stock price higher.

免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。

热议股票

1
2
3
4
5
6
7
8
9
10

{"basename":"/hans","ssrTDKData":{"titleTemplate":"%s - 老虎证券","title":"老虎证券全球投资理财平台| 一站式投资美股新股港股A股","description":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","keywords":"老虎证券,老虎证券开户,老虎券商,老虎证券官网,老虎证券app,tigertrade老虎证券,股票,炒股,新加坡股票交易平台,投资,投资理财","social":{"ogDescription":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/hans/news/1154305961"},"companyName":"老虎证券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"1154305961\",edition:\"fundamental\",,,undefined,":{"share":"https://ttm.financial/m/news/1154305961?lang=zh_CN&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-02-28 23:28","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1154305961","market":"hk","top_or_hot":-1,"title":"Stock Track | Summit Therapeutics Soars 5.14% as Goldman Initiates Coverage with Buy Rating on Promising Drug","media":"Stock Track","content":"<p>Summit Therapeutics PLC (SMMT) witnessed a surge of 5.14% during the intraday trading session on Friday, reflecting the positive sentiment following Goldman Sachs' initiation of coverage on the stock.</p>\n<p>Goldman Sachs analyst Salveen Richter initiated coverage on Summit Therapeutics with a Buy rating and a price target of $42. The analyst is optimistic about the potential of Summit's lead drug candidate, ivonescimab, which is currently undergoing clinical trials for the treatment of Duchenne muscular dystrophy (DMD).</p>\n<p>Analysts believe that if the trials for ivonescimab prove successful, it could potentially become a game-changer in the treatment of DMD, a rare genetic disorder characterized by progressive muscle degeneration. The positive coverage from a prominent investment bank like Goldman Sachs has boosted investor confidence in Summit Therapeutics, driving the stock price higher.</p>","source":"ai_movement_en","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Stock Track | Summit Therapeutics Soars 5.14% as Goldman Initiates Coverage with Buy Rating on Promising Drug</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nStock Track | Summit Therapeutics Soars 5.14% as Goldman Initiates Coverage with Buy Rating on Promising Drug\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1086803395\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/a81accab1e7ee4144dc051f71903a390);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Stock Track </p>\n<p class=\"h-time\">2025-02-28 23:28</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>Summit Therapeutics PLC (SMMT) witnessed a surge of 5.14% during the intraday trading session on Friday, reflecting the positive sentiment following Goldman Sachs' initiation of coverage on the stock.</p>\n<p>Goldman Sachs analyst Salveen Richter initiated coverage on Summit Therapeutics with a Buy rating and a price target of $42. The analyst is optimistic about the potential of Summit's lead drug candidate, ivonescimab, which is currently undergoing clinical trials for the treatment of Duchenne muscular dystrophy (DMD).</p>\n<p>Analysts believe that if the trials for ivonescimab prove successful, it could potentially become a game-changer in the treatment of DMD, a rare genetic disorder characterized by progressive muscle degeneration. The positive coverage from a prominent investment bank like Goldman Sachs has boosted investor confidence in Summit Therapeutics, driving the stock price higher.</p>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"SMMT","symbol_name":"Summit Therapeutics PLC","start_time":0,"source_url":"","article_id":"1154305961","we_media_id":"1086803395","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1154305961","pubTimestamp":1740756509,"columns":[],"sourceInfo":{"source_id":"ai_movement_en","name":"Stock Track"},"weMediaInfo":{"media_name":"Stock Track","introduction":"Track stock‘s movements and relevant news","home_visible":1,"id":"1086803395","head_image":"https://static.tigerbbs.com/a81accab1e7ee4144dc051f71903a390"},"summary":"Summit Therapeutics PLC  witnessed a surge of 5.14% during the intraday trading session on Friday, reflecting the positive sentiment following Goldman Sachs' initiation of coverage on the stock.Goldman Sachs analyst Salveen Richter initiated coverage on Summit Therapeutics with a Buy rating and a price target of $42. The analyst is optimistic about the potential of Summit's lead drug candidate, ivonescimab, which is currently undergoing clinical trials for the treatment of Duchenne muscular dyst","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"SMMT":"Summit Therapeutics PLC"},"translate_title":"高盛对有前途的药物给予买入评级，股价赛道Summit Therapeutics飙升5.14%","themeId":"","isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"SMMT":1},"content_text":"Summit Therapeutics PLC (SMMT) witnessed a surge of 5.14% during the intraday trading session on Friday, reflecting the positive sentiment following Goldman Sachs' initiation of coverage on the stock.\nGoldman Sachs analyst Salveen Richter initiated coverage on Summit Therapeutics with a Buy rating and a price target of $42. The analyst is optimistic about the potential of Summit's lead drug candidate, ivonescimab, which is currently undergoing clinical trials for the treatment of Duchenne muscular dystrophy (DMD).\nAnalysts believe that if the trials for ivonescimab prove successful, it could potentially become a game-changer in the treatment of DMD, a rare genetic disorder characterized by progressive muscle degeneration. The positive coverage from a prominent investment bank like Goldman Sachs has boosted investor confidence in Summit Therapeutics, driving the stock price higher.","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"movement","news_rank":0,"symbols":[],"gpt_button":1}}}